Table 4.

Summary of Change from Baseline to Week 24 in Liver Biomarkers by ALP Reduction (≥ 25% vs. < 25%)

Biomarker		Participants With ≥ 25% ALP Reduction (n = 5)		Participants With < 25% ALP Reduction (n = 15)*
		Absolute Value	Change From Baseline (%)	Absolute Value	Change From Baseline (%)
GGT (U/L)	Mean (SD)	−163.4 (61.7)	−28.1 (14.5)	−5.1 (186.6)	−0.6 (24.5)
	Median	−135.0	−33.7	−39.0	−7.2
	Min, Max	−235, −109	−45, −12	−491, 362	−32, 44
ALT (U/L)	Mean (SD)	−73.6 (145.5)	−26.6 (34.3)	−11.9 (65.4)	4.8 (35.1)
	Median	−19.0	−20.8	−2.0	−4.3
	Min, Max	−332, 20	−79, 17	−233, 50	−52, 83
AST (U/L)	Mean (SD)	−72.6 (134.5)	−32.9 (35.5)	−4.6 (48.4)	6.4 (44.7)
	Median	−17.0	−27.4	1.0	3.0
	Min, Max	−312, 7	−83, 16	−152, 58	−57, 119
Total bilirubin (mg/dL)	Mean (SD)	−0.1 (0.2)	−11.1 (31.7)	0.5 (1.6)	62.3 (178.5)
	Median	−0.2	−28.6	0.1	20.0
	Min, Max	−0.3, 0.2	−33.3, 40.0	−0.2, 6.2	−40.0, 688.9
Direct bilirubin (mg/dL)	Mean (SD)	−0.1 (0.1)	−28.7 (27.9)	0.4 (1.3)	110.0 (319.2)
	Median	−0.1	−33.3	0.0	0.0
	Min, Max	−0.3, 0.0	−60.0, 0.0	−0.1, 5.0	−50.0, 1250.0
Albumin (g/dL)	Mean (SD)	−0.1 (0.1)	−3.13 (2.6)	0.01 (0.3)	0.3 (7.3)
	Median	−0.1	−2.3	0.1	2.3
	Min, Max	−0.3, 0.0	−6.8, 0.0	−0.7, 0.3	−17.5, 7.9
TE
LSM (kPa)	Mean (SD)	1.2 (0.7)	16.3 (9.9)	1.37 (5.9)	15.6 (57.5)
	Median	0.9	14.3	−0.3	−4.8
	Min, Max	0.5, 2.0	7.8, 32.8	−5.0, 18.6	−41.0, 182.4
Noninvasive biomarkers of liver fibrosis
APRI score	Mean (SD)	−1.1 (2.3)	−32.2 (38.5)	−0.1 (0.6)	5.0 (48.0)
	Median	−0.1	−26.2	−0.01	−4.8
	Min, Max	−5.2, 0.1	−85.2, 15.6	−2.1, 0.6	−56.5, 116.4
FIB‐4 Index score	Mean (SD)	−1.0 (1.7)	−24.3 (30.2)	0.04 (0.4)	6.3 (40.7)
	Median	−0.1	−15.8	0.03	8.8
	Min, Max	−3.9, 0.04	−65.3, 9.1	−0.6, 1.0	−39.2, 86.2

Baseline was selected as the last available predose value.

^*n = 13 for noninvasive biomarkers of liver fibrosis.

Abbreviations: LSM, liver stiffness measure; Max, maximum; Min, minimum.